You are here

Angiogenesis inhibition‐induced hypertension and renal injury: prevention by aspirin?

Description 
Angiogenesis, the formation of new blood vessels from the existing vasculature, is essential for tumor growth and metastasis. In the last decade, angiogenesis inhibitors directed at the vascular endothelial growth factor (VEGF) pathway have become a first line treatment for several malignancies, including some previously untreatable cancers. However, VEGF inhibitors (VEGFi) can induce severe cardiovascular, most frequently hypertension, and renal (proteinuria, glomerular endotheliosis) toxicities. As such, patients treated with VEGFi may have improved cancer outcomes, but at the cost of an increased risk of cardiovascular disease. Furthermore, dose intensity and prolonged use of VEGFi may be limited by cardiovascular side effects, requiring dose reduction and/or early termination of treatment which compromises VEGFi efficacy and patient survival. Novel strategies to prevent these unwanted side effects during angiogenesis inhibition are urgently needed to improve quality of life and survival in cancer patients. In this project we will test the hypothesis that aspirin confers protection during VEGFi therapy with benefits for both the control of arterial pressure and renal function.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
cancer, hypertension, cardio-oncology, vascular biology, kidney, endothelin, prostaglandins
Available options 
PhD/Doctorate
Masters by research
Honours
Time commitment 
Full-time
Top-up scholarship funding available 
No
Physical location 
Clayton Campus
Co-supervisors 
Prof 
Kate Denton

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.